Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.

Lilly Endowment Inc. sold 1,180 shares of Eli Lilly & Co. common stock in multiple transactions on January 16, 2024.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., reported the sale of 1,180 shares of common stock.
• The sales occurred on January 16, 2024, in two separate transactions.
• 1,080 shares were sold at a weighted average price of $645.545 per share.
• An additional 100 shares were sold at a price of $646.17 per share.
• Following these transactions, Lilly Endowment Inc. beneficially owns 99,542,630 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to a significant shareholder's transactions in the company's stock. Such filings are common and provide transparency into insider trading activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The transaction size is relatively small compared to the total holdings of Lilly Endowment Inc., suggesting it is not a major shift in their investment strategy.
• Similar filings are made by other large shareholders and insiders across the pharmaceutical industry, such as those at Pfizer (PFE) and Johnson & Johnson (JNJ).

Stakeholder Impact

• The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price, but is unlikely to cause significant concern given the relatively small size of the transaction compared to their overall holdings.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, LLY